Cubist Pharmaceuticals

Akili adds executives to advance digital medicine product portfolio

Monday, July 3, 2017

Akili Interactive Labs announced the appointment of former Cubist Pharmaceuticals CEO, Robert J. Perez, as executive chairman. Perez has been a commercial advisor with the company for the past year and will now be joining in the more official leadership role as the company continues its growth. Additionally, the company has added former DreamWorks Interactive CEO, Glenn Entis, and former chief game designer at Google, Noah Falstein, as executive advisors.

[Read More]

Ruthigen, Pulmatrix ink merger agreement

Monday, March 16, 2015

Ruthigen, a biopharmaceutical company based in Santa Rosa, Calif., and Pulmatrix, a Lexington, Mass.-based clinical stage biotech, have entered into a definitive merger agreement. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix’s debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen.

[Read More]

Cubist Pharmaceuticals names Robert J. Perez CEO

Thursday, October 23, 2014

Cubist Pharmaceuticals has selected Robert J. Perez as the company’s CEO, effective January, 2015. Perez, who currently is Cubist’s president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist’s board of directors. Current board chair Kenneth M. Bate will become lead independent director.

[Read More]